EUVIMED · CrossrefZeitschrift
Multiple Sclerosis and Demyelinating Disorders
ISSN 2056-6115 · Springer Science and Business Media LLC
Neueste Artikel
A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study
Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints
Neuroprotective therapies for multiple sclerosis and other demyelinating diseases
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life
Stroop event-related potentials as a bioelectrical correlate of frontal lobe dysfunction in multiple sclerosis
Antibodies in acquired demyelinating disorders in children
Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis
The heritage of glatiramer acetate and its use in multiple sclerosis
Hands on Alemtuzumab-experience from clinical practice: whom and how to treat
The link of inflammation and neurodegeneration in progressive multiple sclerosis
Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study
Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis
Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation
Epidemiology of MS in Russia, a historical review
Cytokine profiles in pediatric multiple sclerosis
The still under-investigated role of cognitive deficits in PML diagnosis
Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis
Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation
Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environments
Pediatric versus adult MS: similar or different?
Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case report
Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?
Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis
May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study
Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort study
Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis
The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy
The role of puberty and adolescence in the pathobiology of pediatric multiple sclerosis
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
EUVIMED